Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by CytoAgents

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GP1681

            Therapeutic Area: Immunology Product Name: GP1681

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novotech

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            The new clinical trial is designed to evaluate the use of GP1681 as a potential new medicine to treat the severe immune response to COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GP1681

            Therapeutic Area: Immunology Product Name: GP1681

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Richard King Mellon Foundation

            Deal Size: $0.2 million Upfront Cash: Undisclosed

            Deal Type: Funding July 07, 2020

            Details:

            The funding would accelerate the development of CytoAgents' lead drug candidate, GP1681, an investigational new drug to treat “cytokine storm” induced by COVID-19, from the Richard King Mellon Foundation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GP1681

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $1.6 million Upfront Cash: Undisclosed

            Deal Type: Funding May 13, 2020

            Details:

            The Phase II SBIR grant is non-dilutive funding from the National Institute of Allergy and Infectious Diseases of the NIH and will advance the research of GP1681.